[Experimental study of the antibacterial activity and chemotherapeutic efficacy of the novel glycopeptide eremomycin].
The study of antibacterial and chemotherapeutic activity of eremomycin, a novel glycopeptide antibiotic showed that it inhibited the growth of gram positive and acid fast microbes. The antibacterial spectrum of the novel glycopeptide was close to that of ristomycin and vancomycin. However, the in vitro antibacterial activity of eremomycin was 2-10 times higher than that of ristomycin and vancomycin. It also inhibited the growth of oxacillin resistant microbes at concentrations 5.20 times lower than those of vancomycin and ristomycin. By the therapeutic efficacy in albino mice with staphylococcal or streptococcal sepsis eremomycin was 2-4 times as superior as vancomycin and ristomycin and by the chemotherapeutic indices it was more than 10 times as superior.
Malikova
I V
IV
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects*; D006020:Glycopeptides / Q000494:pharmacology / Q000627:therapeutic use; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D051379:Mice; D012310:Ristocetin / Q000494:pharmacology / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; C053759:eremomycin; D012310:Ristocetin; D014640:Vancomycin
Eksperimental'noe izuchenie antibakterial'noĭ aktivnosti i khimioterapevticheskoĭ éffektivnosti novogo glikopeptidnogo antibiotika éremomitsina.